Revolutionising healing: Gene Editing's breakthrough against sickle cell disease

Blood Rev. 2024 May:65:101185. doi: 10.1016/j.blre.2024.101185. Epub 2024 Mar 7.

Abstract

Recent advancements in gene editing illuminate new potential therapeutic approaches for Sickle Cell Disease (SCD), a debilitating monogenic disorder caused by a point mutation in the β-globin gene. Despite the availability of several FDA-approved medications for symptomatic relief, allogeneic hematopoietic stem cell transplantation (HSCT) remains the sole curative option, underscoring a persistent need for novel treatments. This review delves into the growing field of gene editing, particularly the extensive research focused on curing haemoglobinopathies like SCD. We examine the use of techniques such as CRISPR-Cas9 and homology-directed repair, base editing, and prime editing to either correct the pathogenic variant into a non-pathogenic or wild-type one or augment fetal haemoglobin (HbF) production. The article elucidates ways to optimize these tools for efficacious gene editing with minimal off-target effects and offers insights into their effective delivery into cells. Furthermore, we explore clinical trials involving alternative SCD treatment strategies, such as LentiGlobin therapy and autologous HSCT, distilling the current findings. This review consolidates vital information for the clinical translation of gene editing for SCD, providing strategic insights for investigators eager to further the development of gene editing for SCD.

Keywords: Base editing; CRISPR-Cas9; Drug therapy; HSCT; Prime editing; Sickle cell disease.

Publication types

  • Review

MeSH terms

  • Anemia, Sickle Cell* / genetics
  • Anemia, Sickle Cell* / therapy
  • CRISPR-Cas Systems
  • Fetal Hemoglobin / genetics
  • Gene Editing / methods
  • Hemoglobinopathies* / genetics
  • Humans

Substances

  • Fetal Hemoglobin